Analysts Anticipate Teva Pharmaceutical Industries Limited (NYSE:TEVA) Will Post Earnings of $0.58 Per Share

Wall Street analysts expect Teva Pharmaceutical Industries Limited (NYSE:TEVA) to post earnings per share (EPS) of $0.58 for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Teva Pharmaceutical Industries’ earnings, with estimates ranging from $0.56 to $0.61. Teva Pharmaceutical Industries reported earnings of $0.55 per share during the same quarter last year, which indicates a positive year-over-year growth rate of 5.5%. The company is scheduled to issue its next quarterly earnings report on Wednesday, August 4th.

On average, analysts expect that Teva Pharmaceutical Industries will report full year earnings of $2.64 per share for the current year, with EPS estimates ranging from $2.55 to $2.68. For the next financial year, analysts forecast that the company will report earnings of $2.81 per share, with EPS estimates ranging from $2.65 to $3.03. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that cover Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, April 28th. The company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.55 by $0.08. The firm had revenue of $3.98 billion for the quarter, compared to analyst estimates of $4.04 billion. Teva Pharmaceutical Industries had a negative net margin of 24.45% and a positive return on equity of 21.65%. The company’s revenue for the quarter was down 8.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.76 EPS.

Several research firms recently commented on TEVA. JPMorgan Chase & Co. reissued a “hold” rating and set a $10.00 price objective on shares of Teva Pharmaceutical Industries in a research note on Sunday, March 14th. TheStreet raised shares of Teva Pharmaceutical Industries from a “d+” rating to a “c-” rating in a report on Monday, April 5th. Finally, UBS Group reaffirmed a “neutral” rating and set a $11.00 target price (down from $15.00) on shares of Teva Pharmaceutical Industries in a report on Monday, May 10th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $11.08.

NYSE:TEVA opened at $11.53 on Friday. Teva Pharmaceutical Industries has a one year low of $8.44 and a one year high of $13.30. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.03 and a quick ratio of 0.66. The business’s 50-day simple moving average is $10.63. The company has a market capitalization of $12.59 billion, a price-to-earnings ratio of -3.18, a P/E/G ratio of 0.89 and a beta of 1.46.

In other news, VP David Matthew Stark sold 37,884 shares of the firm’s stock in a transaction dated Tuesday, May 11th. The shares were sold at an average price of $10.22, for a total value of $387,174.48. Following the sale, the vice president now directly owns 40,858 shares in the company, valued at approximately $417,568.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Eric Drape sold 40,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, May 21st. The stock was sold at an average price of $11.01, for a total transaction of $440,400.00. Following the completion of the sale, the vice president now owns 33,128 shares of the company’s stock, valued at $364,739.28. The disclosure for this sale can be found here. Insiders sold a total of 205,128 shares of company stock worth $2,255,252 in the last ninety days. 0.56% of the stock is currently owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in TEVA. Ayalon Holdings Ltd. purchased a new position in Teva Pharmaceutical Industries during the 1st quarter worth approximately $26,000. Freedman Financial Associates Inc. purchased a new position in Teva Pharmaceutical Industries during the 4th quarter worth approximately $38,000. Safeguard Investment Advisory Group LLC purchased a new position in shares of Teva Pharmaceutical Industries during the 4th quarter valued at approximately $42,000. Wealthcare Advisory Partners LLC purchased a new position in shares of Teva Pharmaceutical Industries during the 1st quarter valued at approximately $57,000. Finally, Carolina Wealth Advisors LLC increased its holdings in shares of Teva Pharmaceutical Industries by 13,261.7% during the 1st quarter. Carolina Wealth Advisors LLC now owns 6,280 shares of the company’s stock valued at $72,000 after purchasing an additional 6,233 shares in the last quarter. Institutional investors own 52.60% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Story: What is Liquidity?

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.